HCM
IBRX icon

Highbridge Capital Management’s ImmunityBio IBRX Stock Holding History

Highbridge Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-27,002
Closed -$210K – 1413
2016
Q3 		$210K Buy
+27,002
New +$202K ﹤0.01% 1165
2016
Q2 		– Sell
-10,605
Closed -$87K – 1544
2016
Q1 		$87K Buy
+10,605
New +$99.9K ﹤0.01% 1408

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's IBRX Position: Q4 2016 in Review

Highbridge Capital Management sold out of ImmunityBio (IBRX) in Q4 2016, closing a stake of 27,002 shares — an estimated $210K sold.

Highbridge Capital Management first reported a position in IBRX in Q1 2016 and held it in 2 quarters. The position peaked at $210K in Q3 2016. 68 funds tracked by Wall St. Rank hold IBRX as of Q4 2016.

  • Highbridge Capital Management reported no remaining ImmunityBio position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 27,002 ImmunityBio shares in Q4 2016, an estimated $210K.
  • Highbridge Capital Management first reported a position in ImmunityBio in Q1 2016 and held it in 2 quarters.
  • Highbridge Capital Management's ImmunityBio position peaked at $210K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.